全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Additions to the Human Plasma Proteome via a Tandem MARS Depletion iTRAQ-Based Workflow

DOI: 10.1155/2013/654356

Full-Text   Cite this paper   Add to My Lib

Abstract:

Robust platforms for determining differentially expressed proteins in biomarker and discovery studies using human plasma are of great interest. While increased depth in proteome coverage is desirable, it is associated with costs of experimental time due to necessary sample fractionation. We evaluated a robust quantitative proteomics workflow for its ability (1) to provide increased depth in plasma proteome coverage and (2) to give statistical insight useful for establishing differentially expressed plasma proteins. The workflow involves dual-stage immunodepletion on a multiple affinity removal system (MARS) column, iTRAQ tagging, offline strong-cation exchange chromatography, and liquid chromatography tandem mass spectrometry (LC-MS/MS). Independent workflow experiments were performed in triplicate on four plasma samples tagged with iTRAQ 4-plex reagents. After stringent criteria were applied to database searched results, 689 proteins with at least two spectral counts (SC) were identified. Depth in proteome coverage was assessed by comparison to the 2010 Human Plasma Proteome Reference Database in which our studies reveal 399 additional proteins which have not been previously reported. Additionally, we report on the technical variation of this quantitative workflow which ranges from ±11 to 30%. 1. Introduction Discovery studies using plasma proteomics present challenges due to the technical difficulties associated with measuring the large dynamic range (~10–12 orders of magnitude) of proteins that exist in this medium [1]. Low-abundance proteins, which are of interest for biomarker applications, are often only accessible with involved proteomics workflows that utilize multiple sample fractionation steps. While the development of specific clinical immunoassays would resolve this approach, much work needs to be done in this area. Enrichment strategies for low-abundance plasma proteins rely on immunodepletion of high-abundance proteins [2–5], and, more recently, tandem depletion strategies have been employed [6–9]. For example, proteins present in as little as 1–1.6?μg·mL?1 concentrations are detectable using tandem removal of abundant proteins with human serum albumin and Human 14 (Hu 14) multiple affinity removal system (MARS) columns [9]. A two-stage depletion setup that involves serial IgY and Supermix columns has also been effective in increasing the number of detectable low abundance proteins without affecting quantitative accuracy and precision using isobaric tags for relative and absolute quantification (iTRAQ) [6]. Recently, an updated reference

References

[1]  N. L. Anderson and N. G. Anderson, “The human plasma proteome: history, character, and diagnostic prospects,” Molecular & Cellular Proteomics, vol. 1, no. 11, pp. 845–867, 2002.
[2]  Y. Gong, X. Li, B. Yang et al., “Different immunoaffinity fractionation strategies to characterize the human plasma proteome,” Journal of Proteome Research, vol. 5, no. 6, pp. 1379–1387, 2006.
[3]  H. J. Issaq, Z. Xiao, and T. D. Veenstra, “Serum and plasma proteomics,” Chemical Reviews, vol. 107, no. 8, pp. 3601–3620, 2007.
[4]  J. M. Jacobs, J. N. Adkins, W. J. Qian et al., “Utilizing human blood plasma for proteomic biomarker discovery,” Journal of Proteome Research, vol. 4, no. 4, pp. 1073–1085, 2005.
[5]  C. Tu, P. A. Rudnick, M. Y. Martinez et al., “Depletion of abundant plasma proteins and limitations of plasma proteomics,” Journal of Proteome Research, vol. 9, no. 10, pp. 4982–4991, 2010.
[6]  P. Juhasz, M. Lynch, M. Sethuraman et al., “Semi-targeted plasma proteomics discovery workflow utilizing two-stage protein depletion and off-line LC-MALDI MS/MS,” Journal of Proteome Research, vol. 10, no. 1, pp. 34–45, 2011.
[7]  N. Mortezai, S. N. Harder, C. Schnabel et al., “Tandem affinity depletion: a combination of affinity fractionation and immunoaffinity depletion allows the detection of low-abundance components in the complex proteomes of body fluids,” Journal of Proteome Research, vol. 9, no. 12, pp. 6126–6134, 2010.
[8]  W.-J. Qian, D. T. Kaleta, B. A. Ogata et al., “Enhanced detection of low abundant human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy,” Molecular & Cellular Proteomics, vol. 7, no. 10, pp. 1963–1973, 2008.
[9]  C. M. Shuford, A. M. Hawkridge, J. C. Burnett, and D. C. Muddiman, “Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins (TRAP) in human plasma,” Analytical Chemistry, vol. 82, no. 24, pp. 10179–10185, 2010.
[10]  T. Farrah, E. W. Deutsch, G. S. Omenn et al., “A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas,” Molecular & Cellular Proteomics, vol. 10, Article ID M110.006353, 2011.
[11]  C. D. Aluise, R. A. Sowell, and D. A. Butterfield, “Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1782, no. 10, pp. 549–558, 2008.
[12]  E. Boja, T. Hiltke, R. Rivers et al., “Evolution of clinical proteomics and its role in medicine,” Journal of Proteome Research, vol. 10, no. 1, pp. 66–84, 2011.
[13]  D. Han, S. Moon, H. Kim et al., “Detection of differential proteomes associated with the development of type 2 diabetes in the Zucker rat model using the iTRAQ technique,” Journal of Proteome Research, vol. 10, no. 2, pp. 564–577, 2011.
[14]  M. Latterich, M. Abramovitz, and B. Leyland-Jones, “Proteomics: new technologies and clinical applications,” European Journal of Cancer, vol. 44, no. 18, pp. 2737–2741, 2008.
[15]  N. A. Karp, W. Huber, P. G. Sadowski, P. D. Charles, S. V. Hester, and K. S. Lilley, “Addressing accuracy and precision issues in iTRAQ quantitation,” Molecular and Cellular Proteomics, vol. 9, no. 9, pp. 1885–1897, 2010.
[16]  S. G. Chee, K. C. Poh, K. P. Trong, and P. C. Wright, “Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ),” Journal of Proteome Research, vol. 6, no. 2, pp. 821–827, 2007.
[17]  E. G. Hill, J. H. Schwacke, S. Comte-Walters et al., “A statistical model for iTRAQ data analysis,” Journal of Proteome Research, vol. 7, no. 8, pp. 3091–3101.
[18]  A. L. Oberg, D. W. Mahoney, J. E. Eckel-Passow et al., “Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA,” Journal of Proteome Research, vol. 7, no. 1, pp. 225–233, 2008.
[19]  X. Song, J. Bandow, J. Sherman et al., “iTRAQ experimental design for plasma biomarker discovery,” Journal of Proteome Research, vol. 7, no. 7, pp. 2952–2958, 2008.
[20]  P. K. Chong, C. S. Gan, T. K. Pham, and P. C. Wright, “Isobaric tags for relative and absolute quantitation (iTRAQ) reproducibility: implication of multiple injections,” Journal of Proteome Research, vol. 5, no. 5, pp. 1232–1240, 2006.
[21]  C. Zhou, K. L. Simpson, L. J. Lancashire et al., “Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery,” Journal of Proteome Research, vol. 11, no. 4, pp. 2103–2113, 2012.
[22]  D. W. Mahoney, T. M. Therneau, C. J. Heppelmann et al., “Relative quantification: characterization of bias, variability and fold changes in mass spectrometry data from iTRAQ-labeled peptides,” Journal of Proteome Research, vol. 10, no. 9, pp. 4325–4333, 2011.
[23]  J. A. Kellum, L. Kong, M. P. Fink et al., “Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study,” Archives of Internal Medicine, vol. 167, no. 15, pp. 1655–1663, 2007.
[24]  T. K?cher, P. Pichler, M. Schutzbier et al., “High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method combining the benefits of all,” Journal of Proteome Research, vol. 8, no. 10, pp. 4743–4752, 2009.
[25]  G. W. Horgan, “Sample size and replication in 2D gel electrophoresis studies,” Journal of Proteome Research, vol. 6, no. 7, pp. 2884–2887, 2007.
[26]  E. Ernoult, A. Bourreau, E. Gamelin, and C. Guette, “A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation,” Journal of Biomedicine & Biotechnology, vol. 2010, p. 927917, 2010.
[27]  H. Ye, L. Sun, X. Huang, P. Zhang, and X. Zhao, “A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS,” Molecular and Cellular Biochemistry, vol. 343, no. 1-2, pp. 91–99, 2010.
[28]  D. A. ) Cairns, “Statistical issues in quality control of proteomic analyses: good experimental design and planning,” Proteomics, vol. 11, no. 6, pp. 1037–1048.
[29]  N. A. Karp and K. S. Lilley, “Design and analysis issues in quantitative proteomics studies,” Proteomics, vol. 7, pp. 42–50, 2007.
[30]  Y. Levin, “The role of statistical power analysis in quantitative proteomics,” Proteomics, vol. 11, no. 12, pp. 2565–2567, 2011.
[31]  A. L. Oberg and O. Vitek, “Statistical design of quantitative mass spectrometry-based proteomic experiments,” Journal of Proteome Research, vol. 8, no. 5, pp. 2144–2156, 2009.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133